New findings on pancreatic cancer and glioblastoma treatments presented at major conferences
- Promising results in pancreatic cancer treatment
- Data presented at AACR and AAN 2026
- Focus on glioblastoma expanded access
Diakonos Oncology has shared encouraging findings from its Phase 1 study on pancreatic cancer, revealing significant progress in treatment options. These results were highlighted at both the American Association for Cancer Research (AACR) and the American Academy of Neurology (AAN) 2026 meetings. The data indicates potential benefits in managing this aggressive form of cancer.
In addition to pancreatic cancer results, Diakonos also discussed an expanded access program for glioblastoma, a challenging brain tumor. The company's research aims to improve patient outcomes through innovative therapeutic strategies. The presentations at these prestigious conferences underscore the ongoing commitment to advancing cancer treatment methodologies.
The Phase 1 study's findings contribute to the growing body of research in oncology, particularly in areas where treatment options remain limited. Diakonos Oncology continues to explore new pathways and support initiatives that could benefit patients facing difficult cancer diagnoses.
